Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several grapefruit–CYP3A4–atorvastatin interaction claims are supported qualitatively, but multiple details are unsupported (e.g., furanocoumarin constituents, CYP3A4 involvement beyond label scope, timing window, citrus comparisons, 'up to 50%' magnitude, and specific bleeding risk). There are also unsupported claims about other citrus fruits not interacting.
Category Scores
Accurate Statements
Furanocoumarins in grapefruit (including naringenin and bergamottin) inhibit the enzyme CYP3A4.
Unsupported in provided excerpts: label states grapefruit juice contains components that inhibit CYP 3A4, but does not mention furanocoumarins or specific compounds (naringenin, bergamottin).
CYP3A4 is involved in the metabolism of Lipitor.
Not directly supported in provided excerpts; label describes grapefruit juice components inhibiting CYP 3A4 and increasing plasma concentrations of atorvastatin, but the excerpts do not explicitly state CYP3A4 is involved in atorvastatin metabolism.
When grapefruit is eaten or grapefruit juice is consumed, furanocoumarins can be absorbed into the bloodstream and inhibit CYP3A4 activity.
Partially supported in provided excerpts only at a high level: label says grapefruit juice contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin; the excerpts do not state absorption into the bloodstream or the mechanism via furanocoumarins.
Inhibition of CYP3A4 by grapefruit can increase levels of Lipitor in the bloodstream.
Supported: Section 7.2 says grapefruit juice components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Grapefruit juice should be avoided while taking Lipitor to minimize the risk of interaction.
Not explicitly stated in provided excerpts. Label only states that grapefruit juice contains CYP3A4-inhibiting components and can increase atorvastatin concentrations, especially with excessive consumption (>1.2 liters/day). No 'avoid' instruction is included in the excerpts.
The interaction can occur within 30 minutes to 1 hour after eating grapefruit or drinking grapefruit juice.
Unsupported: no timing window is provided in the excerpts.
Increased Lipitor levels can increase the risk of side effects including muscle pain.
Partially supported: label warns risk of myopathy/rhabdomyolysis is increased with strong CYP3A4 inhibitors and notes grapefruit can increase plasma concentrations of atorvastatin. The excerpts do not explicitly connect grapefruit-induced concentration increases to muscle pain specifically, but muscle adverse effects are discussed under myopathy.
Grapefruit juice can increase the risk of bleeding in patients taking Lipitor.
Unsupported: provided excerpts discuss hemorrhagic stroke risk in a specific 80 mg trial comparison, but do not state grapefruit juice increases bleeding risk.
Other citrus fruits such as oranges, lemons, and limes also contain furanocoumarins.
Unsupported: label excerpts do not discuss other citrus fruits or furanocoumarins in them.
The risk of interaction with other citrus fruits is less significant than with grapefruit.
Unsupported: label excerpts do not compare interaction magnitude across citrus fruits.
Even low doses of Lipitor can interact with grapefruit.
Unsupported: label excerpts do not provide interaction thresholds by atorvastatin dose.
Grapefruit can interact with other medications, including certain antibiotics, blood thinners, and immunosuppressants.
Unsupported as written: label excerpts list strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, itraconazole) as increasing myopathy risk, but do not state grapefruit 'can interact' with those classes. The grapefruit interaction described is specifically with grapefruit juice components.
Unsupported Statements
Furanocoumarins in grapefruit (including naringenin and bergamottin) inhibit the enzyme CYP3A4.
Label excerpts state grapefruit juice contains components that inhibit CYP 3A4, but do not name furanocoumarins or specific compounds (naringenin/bergamottin).
CYP3A4 is involved in the metabolism of Lipitor.
Provided excerpts do not explicitly state CYP3A4 is responsible for atorvastatin metabolism.
When grapefruit is eaten or grapefruit juice is consumed, furanocoumarins can be absorbed into the bloodstream and inhibit CYP3A4 activity.
Label excerpt 7.2 mentions inhibition of CYP3A4 and increased plasma concentrations, but does not describe absorption into bloodstream or the specific mechanism.
Increased Lipitor levels can increase the risk of side effects including muscle pain.
Label supports increased risk of myopathy/rhabdomyolysis with strong CYP3A4 inhibitors and that grapefruit can increase atorvastatin concentrations, but it does not explicitly tie grapefruit-induced concentration increases to muscle pain.
Increased Lipitor levels can increase the risk of liver damage.
Provided excerpts discuss liver enzyme abnormalities and monitoring, but do not state grapefruit-related increased atorvastatin levels increase risk of liver damage.
Increased Lipitor levels can increase the risk of bleeding.
Provided excerpts do not state increased atorvastatin levels (from grapefruit) increase bleeding risk.
The interaction between grapefruit juice and Lipitor can increase the risk of myopathy (muscle damage) by up to 50%.
No quantitative 'up to 50%' risk increase is provided in the excerpts.
Grapefruit juice can increase the risk of bleeding in patients taking Lipitor.
Label excerpt 7.2 does not mention bleeding/hemorrhage risk from grapefruit.
Other citrus fruits such as oranges, lemons, and limes also contain furanocoumarins.
Not addressed in the provided label excerpts.
The levels of furanocoumarins are generally lower in oranges, lemons, and limes than in grapefruit.
Not addressed in the provided label excerpts.
The risk of interaction with other citrus fruits is less significant than with grapefruit.
Not addressed in the provided label excerpts.
Even low doses of Lipitor can interact with grapefruit.
No dose-threshold or statement about 'low doses' is included in the provided excerpts.
The interaction can occur within 30 minutes to 1 hour after eating grapefruit or drinking grapefruit juice.
No onset timing is provided in the provided excerpts.
Furanocoumarin-low fruits such as strawberries, blueberries, and pineapple do not interact with Lipitor.
Not addressed in the provided label excerpts.
Grapefruit can interact with other medications, including certain antibiotics, blood thinners, and immunosuppressants.
The label excerpt 7 provides examples of strong CYP3A4 inhibitors increasing statin myopathy risk, but it does not state grapefruit 'interacts' with those drug classes.
Contradictions
Low
AI Statement
Grapefruit juice should be avoided while taking Lipitor to minimize the risk of interaction.
Label Reference
Label excerpt 7.2 only specifies increased plasma concentrations especially with excessive grapefruit juice consumption (>1.2 liters/day); it does not state 'should be avoided'.
Important Omissions
Dose range/titration details and monitoring instructions are not addressed in the AI claims; however, the user claims appear focused on grapefruit interaction rather than dosing. If the question required comprehensive dosing/administration, those label elements would be omitted.
Importance:
Moderate
Label threshold for 'excessive grapefruit juice consumption (>1.2 liters per day)' is not included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported quantitative risk ('up to 50%'), unsupported bleeding/liver damage claims, and lack of label thresholding may mislead risk perception. Some mechanistic elements are unsupported though the general interaction direction (grapefruit juice can increase atorvastatin plasma concentrations via CYP3A4 inhibition) is consistent with the label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple interaction details are unsupported or not present in the provided label excerpts (specific furanocoumarin compounds, timing window, quantitative myopathy risk, bleeding/liver damage, and other citrus fruit statements).
Suggested Improvement
Limit grapefruit claims to what the label excerpt supports: grapefruit juice contains CYP3A4-inhibiting components that can increase atorvastatin plasma concentrations, especially with excessive consumption (>1.2 L/day). Remove unsupported compound names, timing estimates, quantitative risk estimates, bleeding statements, and unsupported statements about other fruits/medication class interactions.